Skip to content
Search

Latest Stories

People infected with Helicobacter pylori bacterium have higher Alzheimer’s risk

People infected with Helicobacter pylori bacterium have higher Alzheimer’s risk

Around 40 per cent of Britons carry this common stomach bug that is found in contaminated water, food and soil

Researchers at McGill University in Montreal have estimated that about 200,000 cases of Alzheimer’s could be prevented each year by eradicating Helicobacter pylori bacterium, a common stomach bug carried by two in three people worldwide.


In a study, they have found symptomatic Helicobacter pylori infection associated with “moderate but significant” risk of contracting Alzheimer’s, The Times reported.

The risk of contracting Alzheimer’s was 11 per cent higher in adults infected with the bacterium, and it went up to 24 per cent between seven to ten years after the original infection took place.

However, the correlation weakened again after a decade, the researchers concluded after analysing the health data of over four million adults over the age of 50 in the UK.

Found in contaminated water, food and soil, Helicobacter pylori can easily spread from person to person through bodily fluids.

Around 40 per cent of Britons are estimated to carry the bug, which latches on to the sticky mucus of a carrier’s stomach.

While it is unlikely to cause any issues for most people, around 15 per cent of those affected may suffer from symptoms including stomach pains, nausea, weight loss and, potentially, and ulcers.

How exactly the bug increases the risk of Alzheimer’s disease is not known, but the McGill University research team suggested that it might be able to travel to the brain, where it inflames cells and cause neurodegeneration.

Dr Paul Brassard, the study’s senior author, has expressed hope that their findings could help protect people from Alzheimer’s, which affects around 900,000 people in Britain, in the future.

Dementia cases are expected to triple in the next 40 years, but there’s limited effective treatment options for this disease, Brassard added.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less